Founders Capital Management (Texas)’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $86.4K | Hold |
1,500
| – | – | 0.04% | 107 |
|
|
2026
Q1 | $91K | Hold |
1,500
| – | – | 0.04% | 94 |
|
|
2025
Q4 | $80.9K | Hold |
1,500
| – | – | 0.04% | 100 |
|
|
2025
Q3 | $67.7K | Buy |
1,500
+300
| +25% | +$14K | 0.04% | 110 |
|
|
2025
Q2 | $55.5K | Hold |
1,200
| – | – | 0.03% | 125 |
|
|
2025
Q1 | $73.2K | Hold |
1,200
| – | – | 0.05% | 100 |
|
|
2024
Q4 | $67.9K | Hold |
1,200
| – | – | 0.04% | 114 |
|
|
2024
Q3 | $62.1K | Hold |
1,200
| – | – | 0.04% | 125 |
|
|
2024
Q2 | $49.8K | Hold |
1,200
| – | – | 0.03% | 140 |
|
|
2024
Q1 | $65.1K | Buy |
1,200
+100
| +9% | +$5.09K | 0.04% | 118 |
|
|
2023
Q4 | $56.4K | Buy |
1,100
+100
| +10% | +$5.25K | 0.04% | 128 |
|
|
2023
Q3 | $58K | Hold |
1,000
| – | – | 0.04% | 122 |
|
|
2023
Q2 | $64K | Hold |
1,000
| – | – | 0.05% | 125 |
|
|
2023
Q1 | $69K | Hold |
1,000
| – | – | 0.05% | 115 |
|
|
2022
Q4 | $72K | Hold |
1,000
| – | – | 0.05% | 105 |
|
|
2022
Q3 | $71K | Hold |
1,000
| – | – | 0.06% | 103 |
|
|
2022
Q2 | $77K | Buy |
1,000
+1
| +0.1% | +$76 | 0.06% | 100 |
|
|
2022
Q1 | $62K | Hold |
999
| – | – | 0.04% | 111 |
|
|
2021
Q4 | $62K | Buy |
999
+100
| +11% | +$5.87K | 0.04% | 111 |
|
|
2021
Q3 | $53K | Buy |
899
+400
| +80% | +$26.3K | 0.04% | 117 |
|
|
2021
Q2 | $33K | Hold |
499
| – | – | 0.02% | 150 |
|
|
2021
Q1 | $32K | Hold |
499
| – | – | 0.02% | 138 |
|
|
2020
Q4 | $31K | Buy |
+499
| New | +$30.7K | 0.02% | 145 |
|
|
2020
Q1 | $28K | Hold |
499
| – | – | 0.03% | 126 |
|
|
2019
Q4 | $32K | Hold |
499
| – | – | 0.02% | 142 |
|
|
2019
Q3 | $25K | Sell |
499
-701
| -58% | -$32.9K | 0.02% | 161 |
|
|
2019
Q2 | $54K | Hold |
1,200
| – | – | 0.05% | 107 |
|
|
2019
Q1 | $57K | Hold |
1,200
| – | – | 0.05% | 102 |
|
|
2018
Q4 | $62K | Hold |
1,200
| – | – | 0.07% | 92 |
|
|
2018
Q3 | $74K | Hold |
1,200
| – | – | 0.06% | 94 |
|
|
2018
Q2 | $66K | Sell |
1,200
-41,159
| -97% | -$2.22M | 0.06% | 104 |
|
|
2018
Q1 | $2.68M | Hold |
42,359
| – | – | 2.26% | 12 |
|
|
2017
Q4 | $2.6M | Hold |
42,359
| – | – | 2.15% | 15 |
|
|
2017
Q3 | $2.7M | Sell |
42,359
-28
| -0.1% | -$1.64K | 2.24% | 12 |
|
|
2017
Q2 | $2.36M | Buy |
42,387
+3,395
| +9% | +$185K | 2.09% | 16 |
|
|
2017
Q1 | $2.12M | Buy |
+38,992
| New | +$2.14M | 1.91% | 18 |
|
Other funds holding BMY
Founders Capital Management (Texas)'s BMY Position: Q2 2026 in Review
Founders Capital Management (Texas) held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 1,500 shares worth $86.4K. The position accounts for 0.04% of the portfolio, ranked #107.
Founders Capital Management (Texas) first reported a position in BMY in Q1 2017 and has held it in 36 quarters since. The position peaked at $2.7M in Q3 2017. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Founders Capital Management (Texas) held 1,500 shares of Bristol-Myers Squibb worth $86.4K as of Q2 2026.
- Founders Capital Management (Texas) left its Bristol-Myers Squibb share count unchanged in Q2 2026.
- Bristol-Myers Squibb made up 0.04% of Founders Capital Management (Texas)'s portfolio in Q2 2026, its #107 holding.
- Founders Capital Management (Texas) first reported a position in Bristol-Myers Squibb in Q1 2017 and has held it in 36 quarters since.
- Founders Capital Management (Texas)'s Bristol-Myers Squibb position peaked at $2.7M in Q3 2017.
- 2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Founders Capital Management (Texas)'s 13F filing for Q2 2026, filed 21 Jul 2026.